today announced it offers entered into a research agreement with Memorial Sloan-Kettering Malignancy Middle using Agenus‘ proprietary malignancy vaccine technology. The collaboration will test Agenus’ malignancy vaccine in conjunction with antibodies that are intended to target specific markers on tumor cells, such as CTLA-4 and PDL-1. This band of antibodies represents a fresh class of immunotherapeutic brokers that are thought to possess complementary mechanisms of actions with cancer vaccines. The scholarly studies will be performed in the laboratory of Jedd D. Wolchok, M.D., Ph.D., a head in neuro-scientific tumor immunotherapy.CBSNews. This article is normally republished with kind authorization from our close friends at The Kaiser Family members Foundation. You will see the complete Kaiser Daily Health Plan Report, search the archives, or join email delivery of in-depth coverage of wellness policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for Kaisernetwork.org, a free of charge services of The Henry J. Kaiser Family Foundation.